Insider Transactions in Q4 2021 at Vir Biotechnology, Inc. (VIR)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$53,625
$39.95 P/Share
|
|
Dec 28
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Dec 20
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
61,207
+28.46%
|
-
|
|
Dec 20
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,750,000
-8.47%
|
-
|
|
Dec 20
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
102,041
+29.47%
|
-
|
|
Dec 20
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
1,750,000
-8.47%
|
-
|
|
Dec 20
2021
|
Svf Endurance (Cayman) LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
400,022
-1.77%
|
$20,801,144
$52.73 P/Share
|
|
Dec 20
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.19%
|
$834,570
$55.1 P/Share
|
|
Dec 15
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.3%
|
$250,000
$50.88 P/Share
|
|
Dec 15
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Dec 15
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,750
-2.49%
|
$137,500
$50.0 P/Share
|
|
Dec 15
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+2.43%
|
$2,750
$1.53 P/Share
|
|
Dec 14
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$61,875
$45.88 P/Share
|
|
Dec 14
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Dec 01
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,500
-1.91%
|
$322,500
$43.59 P/Share
|
|
Nov 30
2021
|
Janet Napolitano Director |
SELL
Open market or private sale
|
Direct |
1,435
-29.84%
|
$66,010
$46.25 P/Share
|
|
Nov 30
2021
|
Janet Napolitano Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,435
+22.98%
|
$58,835
$41.64 P/Share
|
|
Nov 30
2021
|
Steven J. Rice Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
10,000
-32.68%
|
$500,000
$50.0 P/Share
|
|
Nov 30
2021
|
Steven J. Rice Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+24.63%
|
$120,000
$12.76 P/Share
|
|
Nov 30
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
15,125
-6.22%
|
$710,875
$47.8 P/Share
|
|
Nov 30
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,125
+10.96%
|
$15,125
$1.53 P/Share
|
|
Nov 29
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
17,485
+15.87%
|
-
|
|
Nov 29
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-2.36%
|
-
|
|
Nov 29
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
29,153
+17.02%
|
-
|
|
Nov 29
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-2.36%
|
-
|
|
Nov 29
2021
|
Ann M. Hanly EVP & Chief Technology Officer |
BUY
Open market or private purchase
|
Indirect |
11
+50.0%
|
$473
$43.39 P/Share
|
|
Nov 26
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.96%
|
$546,264
$36.8 P/Share
|
|
Nov 22
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
17,485
+18.87%
|
-
|
|
Nov 22
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-2.31%
|
-
|
|
Nov 22
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
29,153
+20.51%
|
-
|
|
Nov 22
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-2.31%
|
-
|
|
Nov 17
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.38%
|
$180,000
$36.28 P/Share
|
|
Nov 17
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.53%
|
$25,000
$5.17 P/Share
|
|
Nov 16
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$44,000
$32.67 P/Share
|
|
Nov 16
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Nov 03
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.75%
|
$180,000
$36.47 P/Share
|
|
Nov 03
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.53%
|
$25,000
$5.17 P/Share
|
|
Nov 02
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$49,500
$36.94 P/Share
|
|
Nov 02
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Oct 20
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,000
-3.84%
|
$156,000
$39.65 P/Share
|
|
Oct 19
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$52,250
$38.87 P/Share
|
|
Oct 19
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Oct 19
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.48%
|
$591,786
$39.51 P/Share
|
|
Oct 06
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.58%
|
$170,000
$34.56 P/Share
|
|
Oct 05
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$45,375
$33.75 P/Share
|
|
Oct 05
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|